Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR)

Pilot Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

Aged fragile patients are not usually included in clinical trials and efficacy and tolerability of the different available treatments in this population are unknown.

Conversely, ageing has been associated with a decrease in the efficacy of immune checkpoint inhibitors due to a decline in the effectiveness of the immune system (immunosenescence). In the Checkmate 025 trial comparing nivolumab with everolimus, the Hazard Ratio (HR) in patients older than 75 years old favoured everolimus, 1.23 (0.66-2.31). Thus, TKis might be a better treatment option for this population. However, the absence of data and concerns about possible secondary effects associated, can preclude clinicians to treat aged fragile patients with cabozantinib. A pilot phase II trial would help to have data on safety and efficacy of cabozantinib in this aged fragile population.

In METEOR trial around 60% of patients reduced the dose of cabozantinib because of toxicity and tolerance problems. It is suspected that the efficacy of cabozantinib in the population to be included in this trial (aged and fragile) will be similar to that observed in CABOSUN trial (disease control rate around 75%). However, there is no information available in this group of patients. On the other hand, in the >75 years old subgroup within the METEOR trial, 37% discontinued due to adverse events, 85% needed dose reductions and median average daily dose was 33,6 mg. For this reason, the cabozantinib initial dose chosen for patients to be included in this study is 40 mg/day.

Study Overview

• Status: Completed
• Conditions: Old Age; Debility; Renal Carcinoma Metastatic
• Intervention / Treatment: Drug: Cabozantinib

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 2

Contacts and Locations

Study Locations

• Spain
  • Ciudad Real, Spain
    • Hospital de Ciudad Real
  • L'Hospitalet De Llobregat, Spain
    • ICO l'Hospitalet
  • Las Palmas De Gran Canaria, Spain
    • Hospital Insular de Gran Canarias
  • Lugo, Spain
    • Hospital Lucus Augustí
  • Madrid, Spain
    • Hospital Infanta Sofia
  • San Sebastián, Spain
    • Hospital Universitario de Donostia
  • Valencia, Spain, 46009
    • Fundación Instituto Valenciano de Oncología
  • Valencia, Spain
    • Hospital Universitario La Fe
  • Valencia, Spain
    • Hospital Doctor Peset
  • Valladolid, Spain
    • Hospital Clínico de Valladolid

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 70 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Documented histological or cytological diagnosis of renal cell cancer.
2. Measurable disease per RECIST 1.1 as determined by the investigator.
3. Metastatic disease.
4. Patient must have signed the informed consent document.
5. Capable of understanding and complying with the protocol requirements.
6. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2.
7. Patients aged >70 years old with Society of Geriatric Oncology (SIOG) defined fragile population or patients >75 years with or without SIOG defined fragility.
8. No previous treatment for Metastatic Renal Cell Carcinoma (mRCC)
9. Adequate organ function based on standard laboratory tests including haematology, serum chemistry, lipids, coagulation, thyroid function, and urinalysis.
10. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.

Exclusion Criteria:

1. Previous treatment for mRCC.
2. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before inclusion.
3. Known brain metastases or cranial epidural disease unless adequately treated and stable for at least 3 months before inclusion.
4. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors or low molecular weight heparins (LMWH).
5. Chronic treatment with corticosteroids or other immunosuppressive agents
6. Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders, Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation, Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 3 months before inclusion, Cavitating pulmonary lesion(s) or known endobronchial disease manifestation and/or Lesions invading major pulmonary blood vessels.
7. Major surgery within 2 months before inclusion.
8. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 msec within 10 days before inclusion.
9. Inability to swallow tablets or capsules.
10. Previously identified allergy or hypersensitivity to components of the study treatment formulation.
11. Diagnosis of another malignancy within 2 years before inclusion, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cabozantinib; Cabozantinib 40 mg p.o. once daily in 28-day cycles.	Drug: Cabozantinib; Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	Complete Response (CR) evaluated by Evaluation Criteria In Solid Tumors (RECIST) 1.1 according to investigator criteria.	Up to 24 months
Objective Response Rate (ORR)	Partial Response (PR) evaluated by Evaluation Criteria In Solid Tumors (RECIST) 1.1 according to investigator criteria.	Up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events	Adverse Events (AEs) experienced by patients. AEs will be assessed according to National Cancer Institute-Common Terminology Criteria (NCI-CTC) v 5.0 criteria.	Up to 24 months
Disease Control Rate (DCR)	Complete Response (CR) evaluated by RECIST 1.1 criteria according to investigator criteria.	Up to 24 months
Disease Control Rate (DCR)	Partial Response (PR) evaluated by RECIST 1.1 criteria according to investigator criteria.	Up to 24 months
Disease Control Rate (DCR)	Stable Disease (SD) evaluated by RECIST 1.1 criteria according to investigator criteria.	Up to 24 months
Progression Free Survival (PFS)	Time in months since the patient's study enrolment until patient progression according to RECIST 1.1 criteria	Since the patient's study enrolment until patient progression, assessed up to 24 months
Overall Survival (OS)	It is time in months since the patient's study enrolment until death	Since the patient's study enrolment until death assessed up to 24 months

Collaborators and Investigators

• Sponsor: Spanish Oncology Genito-Urinary Group
• Collaborators: Apices Soluciones S.L.
• Investigators: Principal Investigator: Miguel A Climent, MD, FIVO

Study record dates

Study Major Dates

• Study Start (Actual): February 17, 2020
• Primary Completion (Actual): November 22, 2023
• Study Completion (Actual): November 22, 2023

Study Registration Dates

• First Submitted: October 15, 2019
• First Submitted That Met QC Criteria: October 17, 2019
• First Posted (Actual): October 22, 2019

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 8, 2024
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: old age; renal carcinoma; fragile
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Neoplasms; Carcinoma, Renal Cell; Carcinoma; Frailty
• Other Study ID Numbers: CABOMAYOR; 2019-001639-30 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No